TY - JOUR
T1 - Modeling cholinergic aspects of schizophrenia
T2 - Focus on the antimuscarinic syndrome
AU - Barak, Segev
N1 - Funding Information:
The research by the author described in this review was supported by the Israel Science Foundation (ISF; grant no. 1234/07) and by the Josef Sagol Fellowship Program in Brain Studies at Tel Aviv University.
PY - 2009/12/7
Y1 - 2009/12/7
N2 - Symptoms of schizophrenia, commonly divided into positive symptoms, negative symptoms, and cognitive impairments, exhibit different sensitivity to pharmacological treatments. As such, they are typically modeled in animals by behavioral effects of drugs that evoke these symptoms in humans, such as amphetamine or phencyclidine (PCP). Despite the fact that muscarinic antagonists also evoke a schizophrenia-like syndrome ("antimuscarinic syndrome") and findings of cholinergic-related alterations in brains of schizophrenia patients, modeling schizophrenia using muscarinic manipulations has been infrequently considered, and the effects of muscarinic blockade on behavioral tasks relevant to schizophrenia have not been adequately characterized. The present review surveys recent attempts to model schizophrenia-related symptoms using manipulations causing cholinergic dysfunction, particularly muscarinic blockade, in well validated behavioral models of schizophrenia, such as prepulse inhibition and latent inhibition.
AB - Symptoms of schizophrenia, commonly divided into positive symptoms, negative symptoms, and cognitive impairments, exhibit different sensitivity to pharmacological treatments. As such, they are typically modeled in animals by behavioral effects of drugs that evoke these symptoms in humans, such as amphetamine or phencyclidine (PCP). Despite the fact that muscarinic antagonists also evoke a schizophrenia-like syndrome ("antimuscarinic syndrome") and findings of cholinergic-related alterations in brains of schizophrenia patients, modeling schizophrenia using muscarinic manipulations has been infrequently considered, and the effects of muscarinic blockade on behavioral tasks relevant to schizophrenia have not been adequately characterized. The present review surveys recent attempts to model schizophrenia-related symptoms using manipulations causing cholinergic dysfunction, particularly muscarinic blockade, in well validated behavioral models of schizophrenia, such as prepulse inhibition and latent inhibition.
KW - Acetylcholine
KW - Animal models
KW - Antimuscarinic syndrome
KW - Attention
KW - Cognitive impairments
KW - Schizophrenia
KW - Scopolamine
UR - http://www.scopus.com/inward/record.url?scp=69249214135&partnerID=8YFLogxK
U2 - 10.1016/j.bbr.2009.04.006
DO - 10.1016/j.bbr.2009.04.006
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 19376161
AN - SCOPUS:69249214135
SN - 0166-4328
VL - 204
SP - 335
EP - 351
JO - Behavioural Brain Research
JF - Behavioural Brain Research
IS - 2
ER -